2026-04-29T15:24:42Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/267962025-12-18T12:57:24Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Heras-Murillo, Ignacio author Mañanes, Diego author Munné, Pablo author Núñez, Vanessa author Herrera, Jessica author Catalá-Montoro, Mauro author Alvarez, Maite author Del Pozo, Miguel A author Melero, Ignacio author Wculek, Stefanie K author Sancho, David author 2025-04-09 The potential of dendritic cell (DC) vaccination against cancer is not fully achieved. Little is known about the precise nature of the anti-cancer immune response triggered by different natural DC subsets and their relevance in preventing postsurgical tumor recurrence. Here, we use mouse splenic conventional DC1s (cDC1s) or cDC2s pulsed with tumor cell lysates to generate DC vaccines. cDC1-based vaccination induces a stronger effector and memory CD4 and CD8 anti-tumor T cell response, leading to a better control of tumors treated either therapeutically or prophylactically. Using an experimental model of tumor relapse, we show that adjuvant or neoadjuvant cDC1 vaccination improves anti-tumor immune memory, particularly by increasing the infiltrates of CD4 tissue resident memory (Trm) and CD8 memory T cells. This translates into complete prevention of tumor relapses. Moreover, elevated abundance of cDC1s positively correlates with CD4 Trm presence, and both associate with enhanced survival in human breast cancer and melanoma. Our findings suggest that cDC1-based vaccination excels at immune memory induction and prevention of cancer recurrence. Nat Commun. 2025 Apr 9;16(1):3369. Nature Communications 40204706 https://hdl.handle.net/20.500.12105/26796 Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse.